Literature DB >> 2174304

Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors.

T Motoyama1, H Watanabe, S Takeuchi, T Watanabe, S Gotoh, E Okazaki.   

Abstract

The authors studied data of combination assays of tumor markers, because simultaneous elevation of different types of tumor markers in the serum was puzzling. They interpreted such phenomena regarding cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. The tissue expression of the antigens was compared with preoperative serum levels. Several different factors were found to cause the simultaneous elevation of two or three of these markers in the serum. Furthermore, even when the levels of some of the tumor markers were raised in the serum, the ovarian tumor did not always produce the marker by itself. This study indicates that immunohistochemical identification of a marker in tumor tissue is prerequisite to the use of that marker in the serum to monitor disease status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174304     DOI: 10.1002/1097-0142(19901215)66:12<2628::aid-cncr2820661227>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

2.  Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.

Authors:  Sara Ricardo; Lara Marcos-Silva; Cristina Valente; Ricardo Coelho; Rosa Gomes; Leonor David
Journal:  Virchows Arch       Date:  2016-03-22       Impact factor: 4.064

Review 3.  Circulating blood group related carbohydrate antigens as tumour markers.

Authors:  T F Orntoft; E Bech
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.